Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes

Ioulia Vardaki; Sophia Ceder; Dorothea Rutishauser; George Baltatzis; Theodoros Foukakis; Theocharis Panaretakis

doi:10.18632/oncotarget.11663

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes

Ioulia Vardaki, Sophia Ceder, Dorothea Rutishauser, George Baltatzis, Theodoros Foukakis and Theocharis Panaretakis _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:74966-74978. https://doi.org/10.18632/oncotarget.11663

Metrics: PDF 2940 views | HTML 4315 views | ?

Abstract

Ioulia Vardaki1, Sophia Ceder1, Dorothea Rutishauser2,3, George Baltatzis4, Theodoros Foukakis1, Theocharis Panaretakis1

1Department of Oncology-Pathology, Cancer Centrum Karolinska, Karolinska Institutet and University Hospital, Stockholm, Sweden

2Department of Medical Biochemistry and Biophysics, Karolinska Institutet and University Hospital, Stockholm, Sweden

3Science for Life Laboratory, Stockholm, Sweden

4Department of Medicine, School of Health Sciences, University of Athens, Athens, Greece

Correspondence to:

Theocharis Panaretakis, email: [email protected]

Keywords: periostin, biomarkers, exosomes, metastatic, non-metastatic

Received: April 13, 2016 Accepted: August 16, 2016 Published: August 29, 2016

ABSTRACT

Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related deaths in the world. Despite the decrease in mortality due to better diagnostics and palliative care, there is a lack of prognostic markers of metastasis. Recently, the exploitation of liquid biopsies and in particular of the extracellular vesicles has shown promise in the identification of such prognostic markers. In this study we compared the proteomic content of exosomes derived from metastatic and non-metastatic human (MCF7 and MDA-MB-231) and mouse (67NR and 4T1) cell lines. We found significant differences not only in the amount of secreted exosomes but most importantly in the protein content of exosomes secreted from metastatic versus non-metastatic ones. We identified periostin as a protein that is enriched in exosomes secreted by metastatic cells and validated its presence in a pilot cohort of breast cancer patient samples with localized disease or lymph node (LN) metastasis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11663

Publication Alerts

Research Papers:

Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes

Abstract